Navigation Links
Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
Date:10/5/2009

BASKING RIDGE, N.J., Oct. 5 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the Japan Biopharma Conference 2009 at the Conrad Hotel in Tokyo, Japan. Dr. Mazzo's presentation is scheduled for 2:40pm (GMT +9:00) on October 6, 2009. The Conference brings together premier biotechnology companies from North America and Europe with influential Japanese licensing and business development executives. Dr. Mazzo's presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1 is intended for application i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
2. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
3. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
4. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
5. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
6. Regado Biosciences Expands Medical Advisory Board
7. Regado Biosciences Establishes Medical Advisory Board
8. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
9. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
11. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... the product choices to a manageable shortlist of bench and floor scales and ... that fit best with the customer’s industry and application. , Side-by-side product ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2
... producing cellulosic ethanol and the fuel,s promise for the future will be ... Brazil. , ... Sioux Falls, S.D. (Vocus) May 26, 2009-- Rapid advancements ... be highlighted by POET next week at Ethanol Summit 2009 in Sao ...
... Enfant(TM) Pediatric VEP Vision Testing System, Providing Early Detection ... If your child had vision problems, you,d be able ... Goldman, M.D., pediatrician at Children,s Health Center in Gurnee."Children ... deficits, even those they,ve had since birth," says Dr. ...
... Microtest Laboratories is an industry leader in ... with International Conference of Harmonisation (ICH) guidelines, to manufacturers ... part of Microtest,s complete portfolio of contract manufacturing testing ... ICH stability testing helps demonstrate that the product will ...
Cached Biology Technology:POET to Outline Cellulosic Ethanol's Present, Future at Brazil's Ethanol Summit 2009 2Chicago-Area Pediatricians Offering Unique Test to Detect Vision Problems in Children as Young as Six Months of Age 2Microtest Laboratories is an Industry Leader in ICH Stability Testing 2
(Date:8/24/2015)... Calif. , Aug. 24, 2015  Based on its ... recognizes DERMALOG with the 2015 African Biometrics Company of the ... has achieved substantial commercial success in Africa ... , where it has implemented one of the largest ... banks as well as the Central Bank of ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Mass. -- In a new study to be published in ... biologists show that restoring the protein p53,s function in mice ... but restoring the function later on could prevent more advanced ... have known since the 1980s that p53 plays a critical ...
... SPRING HARBOR, N.Y. (Nov. 24, 2010) -- The ... of enzymes"a single compartment with limited internal structure, a ... as summarized in a new book, Cell Biology ... bacterial cells possess distinct intracellular compartments that help orchestrate ...
... of assessing the health of marine ecosystems is an ineffective ... needed, a new study has found.,The findings published this ... changes in fishery catches reflect changes in the structure of ... assess the impacts of fishing on marine ecosystem health. ...
Cached Biology News:MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors 2Scientists question fisheries health test 2
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
... a single fragment based screening project: , ... 96 shape-diverse mixtures of 4 (5 uL each) ... structure refinement , Individual compounds are dissolved ... ca. 50 mM. Supplied in 5 96-well trays. ...
... (Catalog number SCR004) is a specific and ... ES cell differentiation by the determination of ... are the monoclonal antibodies TRA-2-49 (Catalog Number ... permit the detection of Liver / Bone ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
Biology Products: